文献速递肿瘤 PET/CT

参数化方法在表皮生长因子受体突变非小细胞肺癌患者治疗前后动态3'-脱氧-3'-18F-氟胸苷PET/CT中的性能

Parametric Method Performance for Dynamic 3'-Deoxy-3'-18F-Fluorothymidine PET/CT in Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Carcinoma Patients Before and During Therapy.
PubMed 文献 · J Nucl Med · 2016-11-10

本研究在10例接受吉非替尼或厄洛替尼治疗的表皮生长因子受体突变晚期非小细胞肺癌患者中,于基线及治疗开始后7天和28天行动态18F-FLT PET/CT,验证Logan图形分析、双组织房室基函数模型(BFM)和频谱分析(SA)等参数化方法。结果示三种方法所得分布容积(VT)与非线性回归均高度相关(R²≥0.94),SA对噪声最稳健,BFM的K1最准确。作者推荐BFM作为动态18F-FLT PET/CT分析的首选参数化方法,SA亦可使用。

要点

  • Logan、BFM和SA所得VT与非线性回归高度相关(R²≥0.94)。
  • SA的VT图像对体素水平噪声最稳健(重复性系数16% vs >26%)。
  • BFM的K1最准确(R²=0.94),但K1参数整体变异性较大。

核心结论

  • BFM和SA均可在非小细胞肺癌患者治疗前及治疗期间生成定量准确的参数化18F-FLT VT图像。
  • SA对噪声更稳健,而BFM提供的参数化K1数据更准确。
  • 作者推荐BFM作为动态18F-FLT PET/CT分析的首选参数化方法,SA也可使用。

研究设计与样本

  • 10例携带激活型表皮生长因子受体突变、接受吉非替尼或厄洛替尼治疗的晚期非小细胞肺癌患者。
  • 于基线及治疗开始后7天和28天行动态18F-FLT PET/CT。
  • 参数图像采用血浆输入Logan图形分析、双组织房室基函数模型(BFM)和频谱分析(SA)生成,并与可逆双组织房室模型加血容量分数的非线性回归结果比较。
  • 将原始list-mode数据按计数逐次拆分生成两个各含总计数50%的统计等效数据集,分别重建后比较两个重复数据集与原始数据的参数。

主要发现

  • 各参数化方法设置优化后,Logan、BFM和SA所得VT在基线和治疗期间均与非线性回归结果高度相关(R²≥0.94;组内相关系数>0.97)。
  • SA所得VT图像对体素水平噪声最稳健(重复性系数16% vs >26%)。
  • BFM生成的K1值最准确(R²=0.94;组内相关系数0.96)。
  • 参数化K1数据整体变异性较大,但各方法间稳健性无差异(重复性系数80%–84%)。

关键数值与推荐

  • VT与非线性回归相关性:R²≥0.94,组内相关系数>0.97(Logan、BFM、SA)。
  • VT重复性系数:SA为16%,其他方法>26%。
  • K1准确性:BFM的R²=0.94,组内相关系数0.96。
  • K1重复性系数:各方法为80%–84%。

临床怎么用

  • 作者推荐BFM作为动态18F-FLT PET/CT分析的首选参数化方法,SA也可使用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The objective of this study was to validate several parametric methods for quantification of 3'-deoxy-3'-18F-fluorothymidine (18F-FLT) PET in advanced-stage non-small cell lung carcinoma (NSCLC) patients with an activating epidermal growth factor receptor mutation who were treated with gefitinib or erlotinib. Furthermore, we evaluated the impact of noise on accuracy and precision of the parametric analyses of dynamic 18F-FLT PET/CT to assess the robustness of these methods. Methods: Ten NSCLC patients underwent dynamic 18F-FLT PET/CT at baseline and 7 and 28 d after the start of treatment. Parametric images were generated using plasma input Logan graphic analysis and 2 basis functions-based methods: a 2-tissue-compartment basis function model (BFM) and spectral analysis (SA). Whole-tumor-averaged parametric pharmacokinetic parameters were compared with those obtained by nonlinear regression of the tumor time-activity curve using a reversible 2-tissue-compartment model with blood volume fraction. In addition, 2 statistically equivalent datasets were generated by countwise splitting the original list-mode data, each containing 50% of the total counts. Both new datasets were reconstructed, and parametric pharmacokinetic parameters were compared between the 2 replicates and the original data. Results: After the settings of each parametric method were optimized, distribution volumes (VT) obtained with Logan graphic analysis, BFM, and SA all correlated well with those derived using nonlinear regression at baseline and during therapy (R2 ≥ 0.94; intraclass correlation coefficient > 0.97). SA-based VT images were most robust to increased noise on a voxel-level (repeatability coefficient, 16% vs. >26%). Yet BFM generated the most accurate K1 values (R2 = 0.94; intraclass correlation coefficient, 0.96). Parametric K1 data showed a larger variability in general; however, no differences were found in robustness between methods (repeatability coefficient, 80%-84%). Conclusion: Both BFM and SA can generate quantitatively accurate parametric 18F-FLT VT images in NSCLC patients before and during therapy. SA was more robust to noise, yet BFM provided more accurate parametric K1 data. We therefore recommend BFM as the preferred parametric method for analysis of dynamic 18F-FLT PET/CT studies; however, SA can also be used.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Kramer GM, Frings V, Heijtel D, et al. Parametric Method Performance for Dynamic 3'-Deoxy-3'-18F-Fluorothymidine PET/CT in Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Carcinoma Patients Before and During Therapy. J Nucl Med. 2016. PMID: 28572289. doi:10.2967/jnumed.116.178418

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。